Michael Patrick Lux, Naiba Nabieva, Andreas Hartkopf, Jens Huober, Bernhard Volz, Florin-Andrei Ţăran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias Wilhelm Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian M. Kurbacher, Rachel Würstlein, Christoph Thomssen, Michael Untch, Peter Andreas Fasching, Wolfgang Janni, Tanja Fehm, Diethelm Wallwiener, Andreas Schneeweiss, Sara Brucker
- This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
MetadatenAuthor: | Michael Patrick LuxORCiDGND, Naiba Nabieva, Andreas Hartkopf, Jens HuoberGND, Bernhard Volz, Florin-Andrei ŢăranORCiDGND, Friedrich Overkamp, Hans-Christian KolbergGND, Peyman Hadji, Hans TeschORCiDGND, Lothar HäberleORCiD, Johannes Ettl, Diana LüftnerORCiDGND, Markus Wallwiener, Volkmar MüllerORCiDGND, Matthias Wilhelm BeckmannORCiDGND, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian M. KurbacherGND, Rachel WürstleinORCiDGND, Christoph ThomssenORCiDGND, Michael UntchORCiDGND, Peter Andreas FaschingORCiDGND, Wolfgang JanniORCiDGND, Tanja FehmORCiDGND, Diethelm Wallwiener, Andreas SchneeweissORCiDGND, Sara Brucker |
---|
URN: | urn:nbn:de:hebis:30:3-543344 |
---|
DOI: | https://doi.org/10.3390/cancers11010010 |
---|
ISSN: | 2072-6694 |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/30577662 |
---|
Parent Title (English): | Cancers |
---|
Publisher: | MDPI |
---|
Place of publication: | Basel |
---|
Document Type: | Article |
---|
Language: | English |
---|
Year of Completion: | 2018 |
---|
Date of first Publication: | 2018/12/21 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2020/06/24 |
---|
Tag: | HER2 c-erbB2; HER2/neu; T-DM1; advanced breast cancer; antihormone therapy; chemotherapy; lapatinib; metastatic; pertuzumab; trastuzumab |
---|
Volume: | 11 |
---|
Issue: | 1, Art. 10 |
---|
Page Number: | 13 |
---|
First Page: | 1 |
---|
Last Page: | 13 |
---|
Note: | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited |
---|
HeBIS-PPN: | 467081514 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - Namensnennung 4.0 |
---|